Develops drugs for breast cancer with PI3K mutations.
Dec 2024Revenue $0.00/yrExpenses $54.4M/yr
No trendCash runway ≈ 3.7 years from Jun 2026
Figures by year
When will OnKure Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2024, revenue was $0.00 and expenses $54.4M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2024 | $0.00 | $54.4M | −$54.4M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.